Aptevo Therapeutics (APVO)
(Delayed Data from NSDQ)
$0.35 USD
-0.02 (-5.00%)
Updated Aug 28, 2024 03:58 PM ET
After-Market: $0.34 -0.01 (-3.30%) 7:34 PM ET
2-Buy of 5 2
D Value C Growth B Momentum D VGM
Income Statements
Fiscal Year end for Aptevo Therapeutics Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 3 | 12 | 4 | 32 |
Cost Of Goods | 0 | 0 | 0 | 0 | 20 |
Gross Profit | 0 | 3 | 12 | 4 | 13 |
Selling & Adminstrative & Depr. & Amort Expenses | 29 | 32 | 34 | 32 | 55 |
Income After Depreciation & Amortization | -29 | -29 | -21 | -27 | -43 |
Non-Operating Income | 10 | 36 | -8 | -3 | -2 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -19 | 7 | -29 | -31 | -45 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -19 | 7 | -29 | -31 | -45 |
Extras & Discontinued Operations | 1 | 1 | 1 | 13 | 4 |
Net Income (GAAP) | -17 | 8 | -28 | -18 | -40 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -28 | -28 | -20 | -26 | -43 |
Depreciation & Amortization (Cash Flow) | 1 | 1 | 1 | 1 | 0 |
Income After Depreciation & Amortization | -29 | -29 | -21 | -27 | -43 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 0.28 | 0.12 | 0.11 | NA | 0.07 |
Diluted EPS Before Non-Recurring Items | -66.96 | -260.79 | -276.21 | NA | -672.69 |
Diluted Net EPS (GAAP) | -62.56 | 69.16 | -267.40 | -230.40 | -610.82 |
Fiscal Year end for Aptevo Therapeutics Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 6.02 | 6.98 | 6.38 | 6.56 | 8.18 |
Income After SG&A, R&D, and Dept/Amort Expenses | -6.02 | -6.98 | -6.38 | -6.56 | -8.18 |
Non-Operating Income | 0.14 | 0.15 | 0.19 | 0.23 | 0.23 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -5.88 | -6.83 | -6.20 | -6.33 | -7.95 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -5.88 | -6.83 | -6.20 | -6.33 | -7.95 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.29 | 0.00 | 0.00 |
Net Income (GAAP) | -5.88 | -6.83 | -5.90 | -6.33 | -7.95 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 3.52 | 0.69 | NA | 0.29 | 0.15 |
Diluted EPS Before Non-Recurring Items | -1.67 | -9.95 | NA | -22.03 | -54.19 |
Diluted Net EPS (GAAP) | -1.67 | -9.95 | -3.52 | -22.03 | -54.19 |